330 related articles for article (PubMed ID: 35563051)
1. miRNAs in Lymphocytic Leukaemias-The miRror of Drug Resistance.
Sbirkov Y; Vergov B; Mehterov N; Sarafian V
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563051
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL.
Han BW; Feng DD; Li ZG; Luo XQ; Zhang H; Li XJ; Zhang XJ; Zheng LL; Zeng CW; Lin KY; Zhang P; Xu L; Chen YQ
Hum Mol Genet; 2011 Dec; 20(24):4903-15. PubMed ID: 21926415
[TBL] [Abstract][Full Text] [Related]
4. Integrative computational in-depth analysis of dysregulated miRNA-mRNA interactions in drug-resistant pediatric acute lymphoblastic leukemia cells: an attempt to obtain new potential gene-miRNA pathways involved in response to treatment.
Mesrian Tanha H; Mojtabavi Naeini M; Rahgozar S; Moafi A; Honardoost MA
Tumour Biol; 2016 Jun; 37(6):7861-72. PubMed ID: 26700663
[TBL] [Abstract][Full Text] [Related]
5. The role of miRNAs as a big master regulator of signaling pathways involved in lymphoblastic leukemia.
Bagheri M; Sarabi PZ; Mondanizadeh M
J Cell Physiol; 2022 Apr; 237(4):2128-2139. PubMed ID: 35315068
[TBL] [Abstract][Full Text] [Related]
6. miRNAs as cornerstones in chronic lymphocytic leukemia pathogenesis and therapeutic resistance- An emphasis on the interaction of signaling pathways.
Doghish AS; Abulsoud AI; Elshaer SS; Abdelmaksoud NM; Zaki MB; El-Mahdy HA; Ismail A; Fathi D; Elsakka EGE
Pathol Res Pract; 2023 Mar; 243():154363. PubMed ID: 36764011
[TBL] [Abstract][Full Text] [Related]
7. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
9. Role of microRNAs in chronic lymphocytic leukemia (Review).
Zhou XX; Wang X
Mol Med Rep; 2013 Sep; 8(3):719-25. PubMed ID: 23900739
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex.
Musilova K; Mraz M
Leukemia; 2015 May; 29(5):1004-17. PubMed ID: 25541152
[TBL] [Abstract][Full Text] [Related]
11. miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies.
Al-Harbi S; Choudhary GS; Ebron JS; Hill BT; Vivekanathan N; Ting AH; Radivoyevitch T; Smith MR; Shukla GC; Almasan A
Mol Cancer; 2015 Nov; 14():185. PubMed ID: 26537004
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?
Van Roosbroeck K; Calin GA
Semin Oncol; 2016 Apr; 43(2):209-14. PubMed ID: 27040698
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia.
Stankovic T; Marston E
Srp Arh Celok Lek; 2008; 136(3-4):187-92. PubMed ID: 18720757
[TBL] [Abstract][Full Text] [Related]
14. Role of microRNAs in Chronic Lymphocytic Leukemia.
Autore F; Ramassone A; Stirparo L; Pagotto S; Fresa A; Innocenti I; Visone R; Laurenti L
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569845
[TBL] [Abstract][Full Text] [Related]
15. Role of signaling pathways and miRNAs in chronic lymphocytic leukemia.
Li PP; Wang X
Chin Med J (Engl); 2013 Nov; 126(21):4175-82. PubMed ID: 24229693
[TBL] [Abstract][Full Text] [Related]
16. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.
Svirnovski AI; Shman TV; Serhiyenka TF; Savitski VP; Smolnikova VV; Fedasenka UU
Hematology; 2009 Aug; 14(4):204-12. PubMed ID: 19635183
[TBL] [Abstract][Full Text] [Related]
17. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
18. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia.
Zanette DL; Rivadavia F; Molfetta GA; Barbuzano FG; Proto-Siqueira R; Silva WA; Falcão RP; Zago MA
Braz J Med Biol Res; 2007 Nov; 40(11):1435-40. PubMed ID: 17934639
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs in chronic lymphocytic leukemia.
Ward BP; Tsongalis GJ; Kaur P
Exp Mol Pathol; 2011 Apr; 90(2):173-8. PubMed ID: 21168405
[TBL] [Abstract][Full Text] [Related]
20. In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia.
Aleskog A; Larsson R; Höglund M; Kristensen J; Nygren P; Lindhagen E
Anticancer Drugs; 2005 Mar; 16(3):277-83. PubMed ID: 15711179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
